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Abstract
Abnormalities in brains of Alzheimer’s disease (AD) patients are
thought to start long before the first clinical symptoms emerge.
The identification of affected individuals at this ‘preclinical AD’
stage relies on biomarkers such as decreased levels of the amyloid-
b peptide (Ab) in the cerebrospinal fluid (CSF) and positive amyloid
positron emission tomography scans. However, there is little infor-
mation on the longitudinal dynamics of CSF biomarkers, especially
in the earliest disease stages when therapeutic interventions are
likely most effective. To this end, we have studied CSF Ab changes
in three Ab precursor protein transgenic mouse models, focusing
our analysis on the initial Ab deposition, which differs significantly
among the models studied. Remarkably, while we confirmed the
CSF Ab decrease during the extended course of brain Ab deposition,
a 20–30% increase in CSF Ab40 and Ab42 was found around the
time of the first Ab plaque appearance in all models. The biphasic
nature of this observed biomarker changes stresses the need for
longitudinal biomarker studies in the clinical setting and the
search for new ‘preclinical AD’ biomarkers at even earlier disease
stages, by using both mice and human samples. Ultimately, our
findings may open new perspectives in identifying subjects at risk
for AD significantly earlier, and in improving the stratification of
patients for preventive treatment strategies.
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Introduction
Alzheimer’s disease (AD) abnormalities in the brain occur at least
10–20 years before the onset of the first symptoms in both sporadic
and familial AD patients (Holtzman et al, 2011b; Bateman et al,
2012; Buchhave et al, 2012). This early stage has been termed
‘preclinical AD’ and is now an important focus of research as it is
considered the most promising period for successful disease-modify-
ing therapies (Sperling et al, 2013). Thus, a better characterization
of this disease stage is crucial for patient stratification (Fagan & Vos,
2013; Jack & Holtzman, 2013).
Disease-specific biomarkers constitute a reasonable approach to
defining preclinical AD. Among the most promising biomarkers for
characterizing patients at this disease stage are low levels of
amyloid-b 42 peptide (the Ab species that ends with amino acid 42),
high levels of Tau protein in cerebrospinal fluid (CSF) (Shaw et al,
2009; Bateman et al, 2012), atrophy of frontoparietal and temporal
regions as detected by magnetic resonance imaging (Mattsson et al,
2014), and binding of amyloid-specific ligands using positron emis-
sion tomography (PET) (Landau et al, 2013; Roe et al, 2013).
Although the results of these biomarker tests are encouraging in the
preclinical stages close to clinical conversion, earlier preclinical
stages are not yet satisfactorily captured. Ideally, decade-long,
prospective, population-based observational studies are necessary
to provide the precise temporal sequence of the different biomarker
changes (Jack et al, 2013).
Transgenic mice that overexpress human Ab precursor protein
(APP) are useful models for investigating brain Ab pathology, and
recently their translational value for bodily fluid biomarker research
has been demonstrated (Jucker, 2010; Tanghe et al, 2010; Maia et al,
2013). Mouse models allow a direct comparison of brain pathology
and biomarkers, which avoids the diagnostic uncertainty present in
human preclinical AD cohorts. Moreover, the homogeneity of geneti-
cally defined mouse models reduces the inter-individual variability
and facilitates the use of mice in a cross-sectional study design.
We previously reported a 50–80% age-related decline in Ab42,
and to a lesser extent in Ab40 in the CSF of APP transgenic mice
(Maia et al, 2013). The levels of both peptides were inversely corre-
lated with Ab deposition in brain, an observation virtually identical
to that reported in AD patients (Maia et al, 2013). However, our
previous study was designed to capture CSF Ab and total Tau
changes with increasing cerebral Ab deposition and did not allow us
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to resolve putative CSF changes at the initial phase of Ab deposition
or even before the onset of cerebral b amyloidosis.
We have now studied CSF Ab changes in three different APP
transgenic mouse models, focusing our analysis on the time of the
initial Ab deposition in the brain, which differs significantly among
the three mouse models. Remarkably, while we confirmed the CSF
Ab decrease during the later course of brain Ab deposition, we
consistently found a 20–30% increase in CSF Ab40 and Ab42 around
the time of the appearance of the first Ab plaques in all three models.
Results and Discussion
CSF Ab40 and Ab42 exhibit a biphasic profile in APP transgenic
mouse models
APP23 mice expressing human APP with the Swedish mutation
were used to test for CSF Ab40 and Ab42 changes prior to and
during early plaque formation (Sturchler-Pierrat et al, 1997). Both
Ab peptides increased in these mice up to 8 months of age, followed
by a steady decline that was more pronounced for Ab42 than for
Ab40 (Fig 1A and B). At the peak concentrations (8 months), there
was a 22% increase for both CSF Ab40 (95% CI: 110–134) and
Ab42 (95% CI: 108–136) compared to the 3-month-old group
(Fig 1A and B). This inverted U-shaped pattern followed a signifi-
cant quadratic trend for both CSF Ab40 and Ab42 (Fig 1A and B, see
also Fig 2A). The CSF Ab42/40 ratio did not change until 8 months
of age but decreased thereafter (Fig 1C).
To confirm the finding in different models, we used APP24 mice
that express human APP with both the Swedish and London muta-
tions (Abramowski et al, 2008), as well as APP51 mice, which
express human wild-type APP (Bodendorf et al, 2002). Homozygous
APP24 mice were chosen to obtain roughly similar APP expression,
whereas the mutations affect Ab generation or isoform ratio, and
hence the onset of Ab plaque formation. For both APP24 and APP51
mouse lines, CSF Ab40 and Ab42 showed the same inverted
U-shaped pattern (Fig 1D–I) but, strikingly, peaked at a different age
compared to the APP23 model. In the APP24 model, the peak in CSF
Ab occurred at 3–4 months, while in APP51 mice, CSF Ab was
increased at 15 months of age. In APP24 mice, the increase at
3–4 months was 21% for CSF Ab40 (95% CI: 109–132) and 18% for
Ab42 (95% CI: 105–132) when compared to the 2-month-old age
group. In APP51 mice, we observed a 33% rise for CSF Ab40 (95%
CI: 123–142) and 25% for Ab42 (95% CI: 120–130) at 15 months
compared to 3 months of age. Similar to APP23 mice, the CSF Ab40
and Ab42 profiles in APP24 and APP51 mice followed a significant
cubic and quadratic trend, respectively (see also Fig 2D and G).
Increase in CSF Ab40 and Ab42 coincides with the onset of brain
Ab deposition
In largely the same mice as used for CSF measurements, we then
analyzed the amount of total brain Ab by immunoassay and
assessed the onset of Ab deposition by Ab immunohistochemistry
(see Materials and Methods for details). Remarkably, the robust
increase in brain Ab40 and Ab42 in the APP23 mice started
at 8 months, the same age when CSF Ab40 and Ab42 peaked
(Fig 2A–C). Immunohistochemistry revealed that first Ab plaques
appeared at 6 months of age (on average 0.2 plaques per entire
sagittal brain section) but it was only at 8 months of age that more
than one plaque was present per entire sagittal brain section (on
average 1.7 plaques per section) (Fig 3).
Similar observations were made with the other two mouse
lines. For the APP24 mice, a significant increase in brain Ab40 and
Ab42 by immunoassay was found in the 7–8-month-old group
(Fig 2E and F); however, it was already at 3–4 months of age that
at least 1 plaque was present per sagittal brain section (on average
11.4 plaques per section) and thus coinciding with the increased
CSF Ab level. Because most of these plaques were ‘only’ diffuse in
nature, this early deposits may not have been picked up with the
immunoassay. In APP51 mice, both immunoassay and immuno-
staining (on average 3.8 plaques per section) revealed increases at
15 months when CSF Ab was increased (Fig 2G–I). Moreover, in
all three models up to the time when CSF Ab peaked, there was a
positive correlation between Ab levels in brain and Ab40 and Ab42
levels in CSF although only significant for the APP51 model
(Supplementary Fig S1).
sAPPb increases with aging in the APP transgenic mouse lines
To determine whether the age-related changes in CSF Ab concentra-
tion may reflect changes in the amyloidogenic APP processing path-
way, brain sAPPb was measured (Bodendorf et al, 2002). Overall,
we found a significant age-related increase in sAPPb in all of the
models that appeared to be more prominent in APP23 and APP51
mice (Fig 4; Supplementary Fig S2). While the changes in sAPPb
did not allow to demonstrate a consistent relation to the onset of
plaque formation, it is possible that the initial increase in CSF Ab40
and Ab42 is governed by an increase in Ab generation via the
amyloidogenic APP processing pathway. The decline of CSF Ab that
follows the increase (more prominent for Ab42 than 40) may then
be caused by Ab deposition onto amyloid plaques (sequestering
hypothesis). As plaques and their Ab binding sites increase, Ab
sequestration also goes up and eventually outbalances the increase
in Ab with aging in all the models. This then leads to the decline of
soluble Ab that reaches the CSF.
Broadening the preclinical AD concept
The concept of ‘preclinical AD’ is challenging because it relies
largely on biochemical and imaging biomarkers, without neuro-
pathological confirmation (Blennow et al, 2010; Jack & Holtzman,
2013). The most prominent early biomarkers are low levels of Ab42
in CSF and brain retention of amyloid-binding ligands using PET
both reflecting brain deposition of Ab. Studies of long-term longitu-
dinal changes in these biomarkers are still lacking (Roe et al, 2013;
Toledo et al, 2013; Fagan et al, 2014). Even more important, both
low CSF Ab and brain retention of amyloid-binding ligands are
apparent only after substantial Ab deposition in the brain (Iko-
nomovic et al, 2012). Thus, how biomarkers change before a
considerable amount of Ab has already been deposited remains
unknown (Tapiola et al, 2009; Jack et al, 2013). It is therefore
crucial to elucidate the trajectories of these earliest biomarker
changes in order to identify subjects at risk, monitor disease
progression, and, ultimately, characterize the effects of early thera-
peutic interventions (Jack et al, 2013; Fagan et al, 2014).
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In this study, we sought to reveal such initial biomarker changes
using a set of cerebral b-amyloidosis mouse models over-expressing
mutated and wild-type human APP (Sturchler-Pierrat et al, 1997;
Bodendorf et al, 2002; Abramowski et al, 2008). We took advantage
of the different onset of Ab deposition among the three models used
to show that CSF Ab40 and Ab42 levels exhibited a significant
inverted U-shaped profile that peaked when the first Ab plaques
appeared. In fact, although the age when the increase was
observed varied from 3 to 4 months in APP24 mice to 8 months in
APP23 mice and 15 months in APP51 mice, the increase in CSF Ab
consistently coincided with the emergence of deposits in the
different mouse lines.
A B C
D E F
G H I
Figure 1. Human Ab exhibits a biphasic profile in CSF of APP transgenic mice.
A, B Ab40 and Ab42 concentrations in CSF of male APP23 mice (heterozygous; 3 (n = 14), 6 (n = 12), 8 (n = 10), 12 (n = 11), 19 (n = 9), and 25 (n = 6) months of age).
CSF Ab40 (F(1, 56) = 22.351, P < 0.001) as well as CSF Ab42 (F(1, 56) = 38.597, P < 0.001) followed a significant quadratic trend.
C Ab42/40 ratio in CSF of APP23 mice showed a delayed decrease with age (F(1, 56) = 53.894, P < 0.001).
D, E Ab40 and Ab42 concentrations in CSF of male and female APP24 mice (homozygous; 2 (n = 13), 3–4 (n = 16), 7–8 (n = 15), 18–19 (n = 14), 24 (n = 16), and 30
(n = 18) months of age). CSF Ab40 followed a significant quadratic trend (F(1, 86) = 6.678, P = 0.011) and CSF Ab42 best fitted a cubic trend (F(1, 86) = 30.599,
P < 0.001).
F Ab42/40 ratio in CSF of APP24 mice showed a delayed decrease with age (F(1, 86) = 64.936, P < 0.001).
G, H Ab40 and Ab42 in the CSF of female APP51 mice (heterozygous; 3 (n = 6), 15 (n = 8), and 24 (n = 8) months of age; 22 mice in total). CSF Ab40 (F(1, 19) = 37.349,
P < 0.001) as well as CSF Ab42 (F(1, 19) = 107.670, P < 0.001) followed a significant quadratic trend.
I Ab42/40 ratio in CSF of APP51 mice showed a delayed decrease with age (F(1, 19) = 26.367, P < 0.001).
Data information: Post hoc Dunnett’s test was employed for group comparisons, which were always conducted between the youngest group and all other groups.
(Observed CSF Ab40 or Ab42 changes were independent of batch.) All data are represented as group means  SEM; *P < 0.05; **P < 0.01; and ***P < 0.001.
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The increase in CSF Ab40 and Ab42 ranged from 20 to 30%
when compared to the levels determined at the youngest age in each
of the models. Remarkably, in the most recent cross-sectional
biomarker analysis of the dominantly inherited AD network (DIAN)
study, AD mutation carriers revealed a similar, approximately 20%
increase in CSF Ab40 15–20 years before the predicted age of
clinical onset (Fagan et al, 2014). This increase occurred 5–10 years
before the classic biomarker changes associated with the Ab pathol-
ogy became apparent (CSF Ab42 decrease and positivity in amyloid
PET scans). Given the present findings in the mouse models, it is
appealing to suggest that the increase in CSF Ab40 may indeed
reflect the onset of AD plaque deposition in these patients. Unlike
our findings, in the AD mutation carriers, CSF Ab42 did not show a
corresponding increase. However, DIAN includes subjects with
different mutations (APP, presenilin 1, and presenilin 2) character-
ized by a heterogeneous over-production of Ab42, which may have
masked any transient increase (Scheuner et al, 1996; Bateman et al,
2012; Potter et al, 2013). Alternatively, the increase in CSF Ab42
may occur at even earlier ages, a possibility that has not yet been
addressed in the DIAN study.
After the peak, we observed a consistent decrease in CSF Ab42 in
all three models that correlated inversely with the increase in brain
Ab deposition. This was particularly notable in APP24 mice
followed by APP23 mice, as these models deposited considerably
A B C
D E F
G H I
Figure 2. Human Ab in CSF and brain of APP transgenic mice.
A APP23 CSF Ab40 and Ab42 in the same animals as shown in Fig 1. CSF Ab42 and Ab40 are expressed as percentages of levels measured in the youngest age group.
B, C Ab40 and Ab42 (pmol/g wet brain) in the FA-soluble brain extract from the same APP23 mice showed a robust increase with age; ANOVA revealed a significant
cubic trend (F(1, 56) = 221.114, P < 0.001 and F(1, 56) = 370.947, P < 0.001, respectively).
D APP24 CSF Ab40 and Ab42 in the same animals shown in Fig 1 as percentage of the youngest age group.
E, F Ab40 and Ab42 (pmol/g wet brain) in the brain from the same APP24 mice also showed a robust increase with age; ANOVA revealed a significant cubic trend
(F(1, 86) = 202.173, P < 0.001 and F(1, 86) = 139.941, P < 0.001, respectively).
G APP51 CSF Ab40 and Ab42 in the same animals shown in Fig 1 as percentages of levels in the youngest age group.
H, I Ab40 and Ab42 (pmol/g wet brain) in the brain from the same APP51 mice showed a robust increase with age; ANOVA revealed a significant quadratic trend
(F(1, 19) = 12.960, P = 0.002 and F(1, 19) = 19.366, P < 0.001, respectively).
Data information: Post hoc Dunnett’s test group comparisons were always conducted between the youngest group and all other groups. All data are represented as
group means  SEM; *P < 0.05; **P < 0.01; and ***P < 0.001.
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more Ab when compared to APP51 mice. This observation is consis-
tent with previously published work on mouse models of b-amyloi-
dosis (Kawarabayashi et al, 2001; Hong et al, 2011; Maia et al,
2013). It is also in line with what is predicted to occur in human
sporadic and familial AD patients, supporting the concept that once
brain Ab deposition spreads, soluble Ab42 is sequestered in the
plaques and, consequently, reduced in the CSF (Blennow et al,
2010; Holtzman et al, 2011a; Bateman et al, 2012). Our data suggest
that the CSF Ab peak may antedate the CSF Ab drop by a relatively
long period of time. A similar peak may be missed in preclinical AD
patients, as long intervals before the available biomarker changes
(decrease in CSF Ab42, positive amyloid tracer PET) are not
analyzed. Importantly, as the observed CSF Ab profile is biphasic,
identical CSF Ab concentrations may correspond to different patho-
logical stages. This implies that preclinical patient stratification
solely based on this biomarker, could be misleading. Presently,
familial AD patients are stratified based on predicted age of onset of
mutation carriers and sporadic preclinical AD patients are identified
based on amyloid positive markers precluding preventive treatment
trials. Longitudinal analysis of CSF Ab and identification of other
biomarkers defining this disease stage would certainly increase the
possibility of an earlier and timely preventative treatment in better
stratified patients.
To address the potential mechanism underlying the initial CSF
Ab increase, we measured sAPPb in the brain (Bodendorf et al,
2002). In all models, sAPPb increased with age, reflecting a possible
increase in APP processing via the amyloidogenic pathway. Indeed,
an age-related increase in BACE activity in brain has been shown to
occur across different species (Fukumoto et al, 2004; Pera et al,
2013). Our finding suggests that an increase in Ab production may
contribute to the initial increase in CSF Ab until plaque deposition
occurs. However, additional explanations for the present findings,
A
B
Figure 3. Ab plaque pathology in the brains of APP23 mice.
A Ab immunostaining (CN3 antibody, dark blue) in 25-lm sagittal brain sections shows only sparse Ab deposits primarily in the frontal cortex of 6- to 8-month-old
APP23 mice. At 12 months and thereafter, there is a progressive increase in plaque number and size and a progressive involvement of different brain regions. Insets
highlight the plaque characteristics at the different ages. Scale bar, 100 lm.
B The mean number of Ab plaques per section per hemibrain increased with age in 3- to 12-month-old mice. Only four mice were analyzed in the 3-month-old age
group, as APP23 mice do not develop plaques at this age (Sturchler-Pierrat et al, 1997). The 6-, 8-, and 12-month-old age groups included 12, 10, and 11 mice,
respectively (these are the same mice that were used for CSF and brain Ab measurements). Note that the Ab plaques became too numerous and often could no
longer be individually distinguished in the age groups > 12 months of age. Data are represented as group means  SEM.
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such as insufficient Ab clearance with aging as well as an age-
related increase in the half-life of sAPP, cannot be excluded
(Dewachter et al, 2000; Mawuenyega et al, 2010).
Overall, we have shown that CSF Ab40 and Ab42 exhibit a
biphasic profile in murine models of cerebral b-amyloidosis. Most
importantly, in three transgenic mouse lines, we linked the transient
increase in CSF Ab peptides to the age at which Ab plaques emerge.
Mechanistically, the observed CSF Ab changes seem to be governed
distinctively: during the first phase by the increase in Ab and during
the second phase by Ab sequestration in the brain deposits, outbal-
ancing the increased amyloidogenic APP processing especially for
Ab42. The evidence obtained in the three APP transgenic mouse
models is compelling and holds potential to be translated to both
late onset AD and dominantly inherited AD. Indeed, initial hints
from earlier publication (Shoji et al, 2001) and more recent in domi-
nantly inherited AD (Fagan et al, 2014) suggest that CSF Ab levels
may also increase in early preclinical sporadic AD patients prior to
the well-known decline at later stages. Together with the present
findings in the mice, this will hopefully stimulate the search for
similar changes in the ongoing longitudinal studies and to address
their potential as biomarkers. If confirmed, a CSF Ab peak would
probably take place 20–25 years prior to clinical symptoms and
would be the ideal timing to start primary prevention for AD.
In short, our observations will hopefully pave the way to an even
earlier detection of presymptomatic individuals and a better stratifi-
cation of patients for clinical trials of preventive treatments for AD.
Materials and Methods
APP23 mice
Male 3- to 25-month-old heterozygous APP23 mice (Sturchler-
Pierrat et al, 1997) were all bred at the Hertie Institute for Clinical
Brain Research (Tu¨bingen, Germany). APP23 mice express the
K670M/N671L-mutated human APP (Swedish double mutation)
under control of the neuron-specific Thy1 promoter element at
about 7-fold over endogenous (murine) APP. The mice were gener-
ated on a B6D2 background, but have since been bred with C57BL/
6J mice for over 20 generations. APP23 mice have been reported to
develop plaques beginning at 6–8 months of age, and plaque devel-
opment is faster in females than in males (Sturchler-Pierrat et al,
1997; Eisele et al, 2010). For the present study, only male animals
were used to minimize variability and reduce sample size. All mice
were kept under specific pathogen-free conditions. The experimental
procedures were conducted in accordance with the veterinary office
regulations of Baden-Wu¨rttemberg (Germany) and were approved
by the local Animal Care and Use Committees.
APP24 mice
Male and female 2- to 30-month-old homozygous APP24 mice
(Abramowski et al, 2008) were bred at both the Novartis Mouse
facility (Basel, Switzerland) and the Hertie Institute for Clinical
Brain Research (Tu¨bingen, Germany). The first colony was used for
Ab assessment in CSF and assessment of Ab and sAPPb in brain.
The second colony was used for histological studies, as there were
no fixed brains available from the initial (Basel) cohort. APP24 mice
are on a C57BL/6J background and express K670M/N671L- and
V717I (London)-mutated human APP, the latter of which increases
the Ab42/40 ratio. Expression is under control of the neuron-specific
Thy1 promoter element, and in homozygous mice, it is about 7-fold
over endogenous (murine) APP. Homozygous APP24 mice develop
the first plaques between 3 and 4 months of age without a promi-
nent gender difference. The experimental procedures were
conducted in accordance with the veterinary office regulations of
Basel (Switzerland) and Baden-Wu¨rttemberg (Germany) and were
approved by the local Animal Care and Use Committees.
A B C
Figure 4. Brain sAPPb shows an age-related increase in APP23, APP24, and APP51 mice.
sAPPbwasmeasured in Triton X-100 brain extracts from largely the samemice as analyzed in Figs 1 and 2 and is expressed as percentages of levels measured in the youngest
age group.
A Swedish sAPPb showed an age-dependent increase in APP23 mice following a linear trend (F(1, 83) = 52.914, P < 0.001); APP23 from two independent batches were
included in this analysis (see Materials and Methods and Supplementary Fig S2 for details).
B Swedish sAPPb showed an age-dependent increase in APP24 mice following a linear trend (F(1, 84) = 11.264, P = 0.001).
C Human wild-type sAPPb showed an age-dependent increase in APP51 following a quadratic trend (F(1, 18) = 68.980, P < 0.001).
Data information: Post hoc Dunnett’s test group comparisons were always conducted between the youngest group and all other groups. All data are represented as
group means  SEM; *P < 0.05; **P < 0.01; and ***P < 0.001. For absolute values, see Supplementary Fig S2.
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APP51 mice
Female 3- to 26-month-old heterozygous APP51 mice (Bodendorf
et al, 2002) were bred at both the Novartis Mouse facility (Basel,
Switzerland) and the Hertie Institute for Clinical Brain Research
(Tu¨bingen, Germany). The first colony was used for Ab assessment
in CSF and for the assessment of Ab and sAPPb in brain. The second
colony was used for histological studies, as there were no fixed brains
available from the initial (Basel) cohort. APP51 mice express the
human wild-type APP under control of the neuron-specific Thy1
promoter element at about 7-fold over endogenous (murine) APP and
were bred on a C57BL/6J background. APP51 mice develop the first
plaques between 13 and 15 months of age. The experimental proce-
dures were conducted in accordance with the veterinary office regula-
tions of Basel (Switzerland) and Baden-Wu¨rttemberg (Germany) and
were approved by the local Animal Care and Use Committees.
CSF collection and tissue harvesting
CSF collection was undertaken as described previously adopting a
standardized protocol for CSF collection matching human QC proto-
cols (Maia et al, 2013). Briefly, CSF was collected at a fixed time-
point to minimize circadian CSF Ab variations (Kang et al, 2009).
After anesthetizing the mice, CSF was immediately collected from the
cisterna magna. CSF samples were then centrifuged at 13,000 g for
30 s, assessed macroscopically for blood contamination, aliquoted
(5 ll), and stored at 80°C until use. Blood-contaminated samples
were not analyzed. Thereafter, mice were perfused with ice-cold ster-
ile PBS. The brain was removed, and one hemibrain (left) was snap-
frozen in dry ice and stored at 80°C until use. The other hemibrain
(right) was fixed in 4% paraformaldehyde with 0.1 M PBS, pH 7.6,
for 48 h at 4°C, immersed in 30% sucrose for an additional 24 h at
4°C, snap-frozen in 2-methylbutane, and stored at80°C.
Biochemical analysis of brain tissue
Hemibrains from APP23 mice were homogenized at 10% (w/v) in
homogenization buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM
EDTA, and Complete protease inhibitor cocktail from Roche Molecu-
lar Biochemicals) on ice using a Dounce (IKA, Staufen, Germany) or
Precellys (Bertin, Montigny-le-Bretonneux, France) homogenizer.
The homogenized brain tissue was aliquoted and stored at 80°C
until use. For Ab measurements, the homogenates were extracted as
follows: Aliquots were thawed on ice, mixed 1:3.2 with cold formic
acid (FA) (min. 96% purity, Sigma, St. Louis, MO, USA), sonicated
for 35 s at 4°C, and spun at 25,000 g at 4°C for 1 h. The supernatant
was collected as the ‘FA-soluble fraction’ and equilibrated (1:20) in
neutralization buffer (1 M Tris base, 0.5 M Na2HPO4, 0.05% NaN3).
The brain tissue from the APP24 and APP51 mice was similarly
prepared with the following deviations: First, forebrains (hemibrains
without the cerebellum) were used, and second, homogenization
was done at 10% (w/v) in TBS (30 mM Tris–HCl pH 7.6, 137 mM
NaCl, Complete protease inhibitor cocktail, Roche) by vigorous shak-
ing with metal beads in a Retsch mill, followed by brief sonication.
For sAPPbmeasurements, we used Triton X-100 (Sigma, St. Louis,
MO, USA) extracts as previously described (Abramowski et al,
2008). In brief, the homogenates were thawed on ice, mixed 1:1 with
2% Triton X-100–TBS solution with regular vortexing for 15 min,
and spun at 20,800 g at 4°C for 15 min, and finally the supernatants
were collected as the ‘Tx-soluble brain extracts’ for analysis.
Electrochemiluminescence-linked immunoassay for Ab in CSF and
brain extracts
Ab concentrations in CSF and brain extracts from APP transgenic
mice were determined with an electrochemiluminescence-linked
immunoassay using the MSD 96-well MULTI-SPOT Human
(6E10) Ab Triplex Assay (Meso Scale Discovery, Gaithersburg, MD,
USA). CSF was analyzed according to the manufacturer’s instruc-
tions, as described previously (Maia et al, 2013). Brain Ab detection
was done in Ab triplex plates. FA-soluble brain samples were
diluted 1:10 to 1:100 in dilution buffer and measured. Measure-
ments were performed by a blinded researcher (ML or JR). Data
analysis used MSD DISCOVERY WORKBENCH software 2.0.
Every sample was tested in duplicate, and those with a coefficient of
variance (CV) over 20% were excluded from the analysis or
repeated if additional material was available. Internal reference
samples were used as a control in every plate, and the results were
adjusted for inter-plate variability. Assay performance was within
the standards of biomarker measurements, and inter-plate CVs for
the different analytes were < 15% (Ab40 inter-plate CV = 12%;
Ab42 inter-plate CV = 15%).
Electrochemiluminescence-linked immunoassay for secreted APP
(sAPP) beta in Triton X-100 brain extracts
Wild-type sAPPb in APP51 brain samples and Swedish sAPPb in
APP23 and APP24 brain samples were determined with an electro-
chemiluminescence-linked immunoassay using the MSD 96-well
MULTI-SPOT Human sAPPb or Swedish sAPPb assay (Meso Scale
Discovery, Gaithersburg, MD, USA). The brains analyzed are from
the same animals that had the CSF Ab measured. In the APP23
model, we used an additional batch of mice to confirm the findings
from the original set of APP23 mice. ‘Tx-soluble brain extracts’ were
diluted up to 1:100,000 in blocking buffer containing 1% Triton
X-100 (in order to stay within the linear range of the assay). Data
analysis used MSD DISCOVERY WORKBENCH software 2.0.
Every sample was tested in duplicate, and those with a coefficient of
variance (CV) over 20% were excluded from the analysis or
repeated. Internal reference samples were used as a control in every
plate, and the results were adjusted for inter-plate variability.
Histology and immunohistochemistry
After freezing, fixed brains were cut into serial, 25-lm-thick sagittal
sections using a freezing–sliding microtome. The sections were
collected in 0.1 M Tris-buffered saline (pH 7.4) and stained immu-
nohistochemically according to previously published protocols using
anti-Ab polyclonal antibody CN3 (Maia et al, 2013).
Quantification of total Ab plaque load
Ab plaque load was quantified on an Ab immunostained set of every
12th systematically sampled, serial, sagittal section throughout the
entire brain, except for 5 APP51 mice from the 15-month age group,
which were sectioned coronally due to processing error. Ab
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immunostained plaques were counted manually using a 10× objec-
tive (0.30 numerical aperture) and a Zeiss Axioskop 2 microscope
(Zeiss, Oberkochen, Germany).
Statistical analysis
The distribution of quantitative data was assessed analyzing Q–Q
plots and confirmed by the Kolmogorov–Smirnov test. Non-
normally distributed variables were logarithmic-transformed. To
examine whether CSF and brain Ab levels change with aging in APP
transgenic mice, a trend test derived from an ANOVA was calcu-
lated. The primary prespecified analysis was whether a linear trend
in CSF and brain Ab levels depending on age was present. Addition-
ally, to improve fit, a quadratic term was investigated exploratory.
Only in case of significant linear trend, subsequent special pairwise
comparisons were done. This is in accordance with the principal of
hierarchically ordered hypotheses. Only differences between the
youngest APP transgenic mouse group and all other age groups
were analyzed using Dunnett’s post hoc test for multiple compari-
sons of the youngest age group to all the others. Correlation analysis
was done using Spearman’s or Pearson’s correlation coefficient,
depending on the bivariate visual distribution of the data. Values
are mean  SEM, unless specified. Statistical tests were justified for
each figure, as appropriate. In all cases, statistical significance was
set at P < 0.05. SPSS version 22 was used for statistical analysis,
and Graphpad Prism version 5 was used to generate the graphics.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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